reamberin and Hepatitis-C--Chronic

To assess efficacy of combined immunocorrection in the treatment of patients with chronic viral hepatitis C (CVHC).. Routine clinicobiochemical tests, examination of immunological homeostasis (cellular immunity, the level of circulating immune complexes - CIC and their molecular composition, macrophagal phagocyting system - MPS) were made in two groups of CVHC patients: the study group (n=68) and control group (n=66). The control patients received standard treatment, the study group received also cyclopheron in combination with reamberin. Cyclopheron was given per os in a single daily dose 600 mg 2 days, then 3 times a week in a dose 150 mg for 48 weeks. Reamberin infusions in a single daily dose 400 ml were made for 5 - 7 days.. CVHC in exacerbation phase is characterized by the presence of secondary immunodeficiency running with T-lymphopenia, low count of peripheral blood lymphocytes with CD4+ phenotype and low immunoregulatory index CD4/CD8, depression of functional activity of T-cells as evidenced by lymphocyte blast transformation test with phytohemagglutinin, inhibition of phagocyting activity of monocytes and inhibition of dermal macrophages. This shows subnormal functional activity of MPS. CVHC runs with accumulation of CIC in blood serum primarily due to increased content of most pathogenic mid- and low-molecular .ifactions of immune complexes. Addition ofcyclopheron and reamberin in combined treatment of CVHC patients promotes normalization of immunological homeostasis which clinically occurs in parallel with achievement of persistent and long-term CVHC remission.. The results of the above investigation support pathogenetic validity and prospects of cyclopheron and reamberin inclusion into combined treatment of CVHC.

Topics: Acridines; Adult; Antigen-Antibody Complex; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon Inducers; Interferon-alpha; Leukocytes, Mononuclear; Lymphocyte Count; Macrophages; Male; Meglumine; Middle Aged; Phagocytosis; Ribavirin; Succinates; T-Lymphocytes; Treatment Outcome; Young Adult

The clinical efficiency of a reamberin and cycloferon combination for the treatment of hepatic cirrhosis (HC) associated with chronic HCV infection has been studied. Immunological investigation of patients carried out before the treatment revealed a significant increase in the level of proinflammatory cytokines (CK) in serum, whereas the level of anti-inflammatory CK changed rather insignificantly. Use of the reamberin - cycloferon combination provided faster clinical-biochemical remission and, in respect of the pathogenetic state, ensured normalization of the CK profile in the blood. Based on these data, it can be considered as pathogenetically proved and clinically feasible and promising to use the reamberin - cycloferon combinations for a complex treatment of patients with HC associated with chronic HCV-infection.

Topics: Acridines; Antiviral Agents; Cytokines; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Inducers; Liver; Liver Cirrhosis; Meglumine; Remission Induction; Succinates; Th1-Th2 Balance; Treatment Outcome; Viral Load